NTS-Polyplex: a potential nanocarrier for neurotrophic therapy of Parkinson's disease
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Nanomedicine has focused on targeted neurotrophic gene delivery to the brain as a strategy to stop and reverse neurodegeneration in Parkinson’s disease. Because of improved transfection ability, synthetic nanocarriers have become candidates for neurotrophic therapy. Neurotensin (NTS)-polyplex is a “Trojan horse” synthetic nanocarrier system that enters dopaminergic neurons through NTS receptor internalization to deliver a genetic cargo. The success of preclinical studies with different neurotrophic genes supports the possibility of using NTS-polyplex in nanomedicine. In this review, we describe the mechanism of NTS-polyplex transfection. We discuss the concept that an effective neurotrophic therapy requires a simultaneous effect on the axon terminals and soma of the remaining dopaminergic neurons. We also discuss the future of this strategy for the treatment of Parkinson’s disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Design and development of polymers for gene delivery
Pack, D. W., Hoffman, A. S., Pun, S., & Stayton, P. S. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1775 · Cited by 2,568 · cited 1×
“The addition of serum is known to stabilize the structure of the neutral polyplex at physiological salt concentrations, thus avoiding the rapid formation of large aggregates,(41) which are generally ineffective gene-delivery agents and can even be dangerous because of embolization of the particles in the lung.(42) In…”
BackgroundSahay, G., Alakhova, D. Y., & Kabanov, A. V. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.01.036 · Cited by 2,181 · cited 17×
“Though a study shows a 23% reduction of these cells at postnatal day 21 in Wnt1-Cre mice,121 other reports showed that chronic deficits in BDNF alone do not affect survival or function of dopaminergic nigrostriatal neurons during aging, as revealed by the study of the BDNF-/- mice.122 The potential utility of GDNF, NR…”
BackgroundMethodInfluentialThe yin and yang of neurotrophin action
Lu, B., Pang, P. T., & Woo, N. H. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1726 · Cited by 1,356
Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo
Tomac, A., Lindqvist, E., Lin, L.-F. H., Ögren, S. O., Young, D., Hoffer, B. J., & Olson, L. (1995) · Nature · doi:10.1038/373335a0 · Cited by 1,079 · cited 15×
“Though a study shows a 23% reduction of these cells at postnatal day 21 in Wnt1-Cre mice,121 other reports showed that chronic deficits in BDNF alone do not affect survival or function of dopaminergic nigrostriatal neurons during aging, as revealed by the study of the BDNF-/- mice.122 The potential utility of GDNF, NR…”
BackgroundInfluentialMarks, W. J., Ostrem, J. L., Verhagen, L., Starr, P. A., Larson, P. S., Bakay, R. A., Taylor, R., Cahn-Weiner, D. A., Stoessl, A. J., Olanow, C. W., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70065-6 · Cited by 596 · cited 3×
“Whereas they have demonstrated relative safety, they have been clinically disappointing.(19,129,130) The negative findings might have resulted from the fact that only advanced-stage PD patients were used for these studies.”
BackgroundResultCaccamo, A., Maldonado, M. A., Bokov, A. F., Majumder, S., & Oddo, S. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1012851108 · Cited by 249
Prensa, L., & Parent, A. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-18-07247.2001 · Cited by 238
Cited by
Leyva-Gómez, G., Cortés, H., Magaña, J. J., Leyva-García, N., Quintanar-Guerrero, D., & Florán, B. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.02.009 · Cited by 102
Razgado-Hernandez, L. F., Espadas-Alvarez, A. J., Reyna-Velazquez, P., Sierra-Sanchez, A., Anaya-Martinez, V., Jimenez-Estrada, I., Bannon, M. J., Martinez-Fong, D., & Aceves-Ruiz, J. (2015) · PLOS ONE · doi:10.1371/journal.pone.0117391 · Cited by 90
Self-citationHernandez-Chan, N. G., Bannon, M. J., Orozco-Barrios, C. E., Escobedo, L., Zamudio, S., De la Cruz, F., Gongora-Alfaro, J. L., Armendáriz-Borunda, J., Reyes-Corona, D., Espadas-Alvarez, A. J., et al. (2015) · Journal of Biomedical Science · doi:10.1186/s12929-015-0166-7 · Cited by 73
“transporter (hDAT) gene promoter in the NTS-polyplex provides a second point of selectivity to transgene expression in vivo [21, 24].”
BackgroundSelf-citation
Metadata
- Authors
- Martinez-Fong, D., Bannon, M. J., Trudeau, L.-E., Gonzalez-Barrios, J. A., Arango-Rodriguez, M. L., Hernandez-Chan, N. G., Reyes-Corona, D., Armendáriz-Borunda, J., & Navarro-Quiroga, I.
- Venue
- Nanomedicine: Nanotechnology, Biology and Medicine
- Publisher
- Elsevier BV
- Published
- 2012-10
- Volume
- 8
- Issue
- 7
- Pages
- 1052-1069
- ISSN
- 1549-9634 (ISSN-L)
- OpenAlex
- W2167222907
- Cited by
- 56
- References
- 7
- FWCI
- 2.44
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.